頁籤選單縮合
| 題 名 | 孕期糖尿病介紹:孕前糖尿病與妊娠糖尿病=Diabetes in Pregnancy: Pregestational Diabetes Mellitus and Gestational Diabetes Mellitus |
|---|---|
| 作 者 | 郭俊亨; | 書刊名 | 內科學誌 |
| 卷 期 | 36:3 2025.06[民114.06] |
| 頁 次 | 頁176-180 |
| 分類號 | 417.346 |
| 關鍵詞 | 孕期糖尿病; 孕前糖尿病; 妊娠糖尿病; 早期篩檢及介入; 周產期併發症; 母嬰代謝異常; Diabetes in pregnancy; Pregestational diabetes mellitus; Gestational diabetes mellitus; Early screening and intervention; Perinatal complications; Maternal and offspring metabolic disorders; |
| 語 文 | 中文(Chinese) |
| DOI | 10.6314/JIMT.202506_36(3).04 |
| 中文摘要 | 孕期糖尿病包括孕前糖尿病及妊娠糖尿病,隨著全球盛行率上升而成為重要健康議題。孕期糖尿病可導致母體及胎兒的嚴重併發症,如孕期高血壓疾病、巨嬰症與先天發育異常,並增加母嬰日後罹患代謝疾病的風險。孕前糖尿病因糖尿病本身常合併的肥胖問題,風險更甚。妊娠糖尿病主要由妊娠中期後胰島素阻抗惡化導致。早期妊娠糖尿病發生於孕期20週前,可能代表更嚴重的代謝異常,與較差的後果相關。如何早期篩檢及介入需更多研究探討。孕期糖尿病的管理需要涵蓋孕前諮詢、孕期篩檢、血糖密切監測、治療及產後追蹤,對降低不良後果及打破跨世代代謝疾病循環具有重要意義。 |
| 英文摘要 | Diabetes in pregnancy (DIP), comprising pregestational diabetes mellitus (PDM) and gestational diabetes mellitus (GDM), presents significant health challenges with increasing global prevalence. PDM refers to type 1 or type 2 diabetes diagnosed before or in early pregnancy, while GDM is characterized by hyperglycemia first detected during mid-to-late pregnancy. DIP significantly increases the risk of maternal and fetal complications, including hypertensive disorders of pregnancy, macrosomia, and congenital anomalies, and predisposes both mothers and offspring to long-term metabolic diseases. PDM, often associated with preexisting obesity, carries even greater risks. GDM arises from progressive pregnancy-induced insulin resistan ce and requires structured management focused on lifestyle interventions and glycemic control. Early gestational diabetes mellitus (eGDM), diagnosed before 20 weeks, may reflect more severe or preexisting metabolic dysfunction and has been linked to worse perinatal and long-term outcomes. Further studies are needed to optimize early screening and treatment strategies for eGDM. Optimal management of DIP involves preconception counseling, pregnancy screening, rigorous glucose monitoring, lifestyle intervention, pharmacological therapies, and postpartum follow-up, which is essential to mitigate adverse outcomes and interrupt the intergenerational cycle of metabolic diseases. |
本系統中英文摘要資訊取自各篇刊載內容。